Total Payments
$357,552
2024 Payments
$11,654
Companies
30
Transactions
332
Medicare Patients
3,789
Medicare Billing
$1.7M
Payment Breakdown by Category
Research$176,485 (49.4%)
Other$81,521 (22.8%)
Consulting$67,675 (18.9%)
Travel$26,261 (7.3%)
Food & Beverage$5,393 (1.5%)
Education$216.40 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $176,485 | 64 | 49.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $81,446 | 23 | 22.8% |
| Consulting Fee | $67,675 | 28 | 18.9% |
| Travel and Lodging | $26,261 | 66 | 7.3% |
| Food and Beverage | $5,393 | 143 | 1.5% |
| Education | $216.40 | 7 | 0.1% |
| Grant | $75.00 | 1 | 0.0% |
Payments by Type
General
$181,067
268 transactions
Research
$176,485
64 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ichnos Sciences Inc. | $148,945 | 31 | $0 (2023) |
| Celgene Corporation | $123,143 | 109 | $0 (2024) |
| Janssen Biotech, Inc. | $18,603 | 31 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $18,601 | 59 | $0 (2023) |
| BeiGene USA, Inc. | $17,264 | 14 | $0 (2024) |
| IGI Inc | $11,207 | 2 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,415 | 7 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,844 | 26 | $0 (2019) |
| BeiGene, Ltd. | $3,000 | 1 | $0 (2021) |
| ABBVIE INC. | $2,002 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,654 | 17 | IGI Inc ($11,207) |
| 2023 | $12,723 | 22 | Ichnos Sciences Inc. ($8,396) |
| 2022 | $43,824 | 19 | Ichnos Sciences Inc. ($28,514) |
| 2021 | $90,457 | 19 | Ichnos Sciences Inc. ($75,702) |
| 2020 | $49,791 | 25 | Ichnos Sciences Inc. ($36,333) |
| 2019 | $47,054 | 63 | Celgene Corporation ($42,761) |
| 2018 | $63,845 | 116 | Celgene Corporation ($37,817) |
| 2017 | $38,204 | 51 | Celgene Corporation ($32,082) |
All Payment Transactions
332 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: Oncology | ||||||
| 12/07/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $78.00 | General |
| Category: Oncology | ||||||
| 11/07/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $24.76 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $45.59 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $9.28 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $77.84 | General |
| Category: Oncology | ||||||
| 09/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: ONCOLOGY | ||||||
| 08/30/2024 | IGI Inc | — | — | Cash or cash equivalent | $45.00 | Research |
| Study: ISB 1342-101 | ||||||
| 05/22/2024 | IGI Inc | — | — | Cash or cash equivalent | $11,162.25 | Research |
| Study: ISB 1342-101 | ||||||
| 05/08/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Oncology | ||||||
| 04/29/2024 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Oncology | ||||||
| 03/05/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: ONCOLOGY | ||||||
| 02/29/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $29.20 | General |
| Category: BioOncology | ||||||
| 02/06/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $23.24 | General |
| Category: Oncology / Rare Diseases | ||||||
| 01/17/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $20.80 | General |
| Category: Hematology | ||||||
| 12/08/2023 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $108.82 | General |
| Category: Oncology | ||||||
| 11/20/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $1,488.00 | Research |
| Study: ISB 1342-101 | ||||||
| 11/17/2023 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,047.50 | General |
| 11/16/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $131.44 | General |
| Category: Oncology | ||||||
| 10/30/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $17.75 | General |
| Category: Hematology | ||||||
| 10/10/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Travel and Lodging | Cash or cash equivalent | $291.00 | General |
| Category: Oncology | ||||||
| 10/10/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2023 | Ichnos Sciences Inc. | — | — | Cash or cash equivalent | $2,908.20 | Research |
| Study: ISB 1342-101 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ISB 1342-101 | Ichnos Sciences Inc. | $148,945 | 31 |
| ISB 1342-101 | IGI Inc | $11,207 | 2 |
| A Study of Ixazomib+Daratumumab+Dexamethasone IDd in Relapsed and-or Refractory Multiple Myeloma RRMM | Takeda Pharmaceuticals U.S.A., Inc. | $4,830 | 25 |
| CC-4047-MM-014 - Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab | Celgene Corporation | $3,048 | 1 |
| A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress | BeiGene, Ltd. | $3,000 | 1 |
| CC-4047-MM-014 | Celgene Corporation | $2,976 | 1 |
| Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab (CC-4047-MM-014) | Celgene Corporation | $1,620 | 1 |
| CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $442.00 | 1 |
| ACE-MM-200 | Celgene Corporation | $417.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 739 | 11,381 | $1.7M | $417,040 |
| 2022 | 27 | 1,065 | 15,509 | $2.0M | $567,175 |
| 2021 | 19 | 686 | 7,309 | $971,079 | $281,961 |
| 2020 | 34 | 1,299 | 17,255 | $1.4M | $416,710 |
Total Patients
3,789
Total Services
51,454
Medicare Billing
$1.7M
Procedure Codes
99
All Medicare Procedures & Services
99 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 29 | 7,560 | $1.2M | $285,562 | 24.3% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 24 | 1,540 | $196,190 | $51,059 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 131 | 290 | $165,341 | $39,658 | 24.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 36 | 73 | $31,079 | $7,638 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 76 | $30,432 | $6,941 | 22.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 133 | 832 | $19,975 | $6,929 | 34.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 51 | 102 | $24,811 | $5,642 | 22.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 56 | 79 | $16,480 | $3,959 | 24.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $13,407 | $3,080 | 23.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 48 | 131 | $8,589 | $2,104 | 24.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 22 | $7,778 | $2,072 | 26.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 15 | 30 | $2,835 | $692.58 | 24.4% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 15 | 20 | $2,307 | $536.20 | 23.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 18 | 32 | $1,632 | $404.84 | 24.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 13 | 13 | $1,233 | $308.23 | 25.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 20 | $848.00 | $194.82 | 23.0% |
| J3475 | Injection, magnesium sulfate, per 500 mg | Office | 2023 | 21 | 324 | $830.00 | $192.55 | 23.2% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 21 | 26 | $221.00 | $52.54 | 23.8% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 12 | 192 | $66.40 | $14.40 | 21.7% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2022 | 33 | 10,980 | $1.5M | $398,166 | 26.4% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 17 | 1,120 | $115,680 | $36,656 | 31.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 109 | 251 | $94,376 | $35,576 | 37.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 70 | 348 | $93,000 | $27,820 | 29.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 134 | 184 | $51,750 | $15,766 | 30.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 51 | 106 | $38,902 | $12,174 | 31.3% |
About Dr. Jeffrey Matous, MD
Dr. Jeffrey Matous, MD is a Hematology & Oncology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1992789036.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Matous, MD has received a total of $357,552 in payments from pharmaceutical and medical device companies, with $11,654 received in 2024. These payments were reported across 332 transactions from 30 companies. The most common payment nature is "" ($176,485).
As a Medicare-enrolled provider, Matous has provided services to 3,789 Medicare beneficiaries, totaling 51,454 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 99 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Denver, CO
- Active Since 12/02/2005
- Last Updated 02/11/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992789036
Products in Payments
- Revlimid (Drug) $96,297
- ISB 1342-101 (Drug) $36,333
- BRUKINSA (Drug) $18,064
- IMBRUVICA (Drug) $16,245
- Imbruvica (Drug) $16,191
- Pomalyst (Drug) $13,279
- Non-Covered $5,415
- Ninlaro (Drug) $4,830
- TECVAYLI (Biological) $2,039
- VENCLEXTA (Drug) $1,943
- DARZALEX (Drug) $1,714
- DARZALEX (Biological) $667.65
- ACY-241 (Drug) $417.00
- SARCLISA (Biological) $131.44
- ADCETRIS (Biological) $103.63
- SOLIRIS (Drug) $92.31
- EPKINLY (Drug) $73.34
- Kyprolis (Biological) $52.26
- Idhifa (Drug) $42.35
- TIBSOVO (Drug) $35.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Denver
Dr. Yousuf Gaffar, Md, MD
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Robert Rifkin, Md, MD
Hematology & Oncology — Payments: $527,544
Hematology & Oncology $527,544
Dr. Peter Mcsweeney, Md, MD
Hematology & Oncology — Payments: $151,717
Hematology & Oncology $151,717
Dr. Moses Raj, Md, MD
Hematology & Oncology — Payments: $135,648
Hematology & Oncology $135,648
Dr. Tara Gregory, M.d, M.D
Hematology & Oncology — Payments: $135,068
Hematology & Oncology $135,068
Peter Forsberg, Md, MD
Hematology & Oncology — Payments: $98,100
Hematology & Oncology $98,100